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INTRODUCTION
Prion diseases are fatal neurodegenerative diseases, transmissible within and in between different species. They occur in humans and animals (12) . Conformational conversion of endogenous cellular prion protein (PrP C ) to its misfolded, disease-associated isoform (PrP Sc ) is key to disease initiation and progression. PrP
Sc is an essential component of the transmissible entity in prion diseases and initiates a series of events leading to neurodegeneration (5, 48) . Presence of proteinase K (PK) resistant PrP Sc serves as a diagnostic criterion to confirm a prion disease (53) , whereas prion infectivity is usually determined by the ability to elicit a prion disease after transmission to animals or susceptible cultured cells (17, 26) . PrP Sc is not congruent with prion infectivity and it is likely that different prion conformers exist (6, 29, 30, 41) .
Although prions replicate in the lymphoreticular system, too, pathology, including astrogliosis, spongiform changes, microglia activation and neuronal loss is exclusively found in the central nervous system (CNS). Molecular mechanisms of neurodegeneration are not fully understood, but might involve neurotoxic conformers of PrP distinct from PrP Sc (52) . Although prion diseases are rare diseases, the prion principle, a sequence of templated misfolding, aggregation and spreading of misfolded proteins, is common to many dementias (2) . In fact, prion mechanisms are described for Alzheimer's disease (AD), Parkinson disease (PD) and amyotrophic lateral sclerosis (ALS) (14, 15, 42) . Therefore, murine prion disease models are valuable tools to study communal principles of protein misfolding, progressive neurodegeneration and cell types involved in disease progression.
Microglia cells are important modulators of disease pathogenesis in neurodegenerative diseases (1, 40, 47) . Although microglia may act beneficially by providing immune surveillance to maintain brain homeostasis (38, 64) , they change their phenotype considerably in disease reacting with sustained proinflammatory signaling and thus contributing to neurodegeneration and progression of disease (1, 33) . The molecular pathways leading to this phenotype switch are not identified yet (1, 24, 60) . In AD, microglia respond to misfolded and aggregated beta-amyloid (Ab), clustering around deposited Ab (47) . Stimulation of microglial Ab clearance in AD-mouse models is accompanied by reduction of AD brain pathology (59) and may represent a potential target for therapy. However, the effectiveness of microglial Ab clearance diminishes with age and disease state (37) . In prion disease, microglia seem to be neuroprotective (62) , however, once microglia numbers are upregulated during the course of disease, they do not exhibit efficient prionclearing capacity (24) .
Recently, we showed that the brain lesion profile of mice infected intraperitoneally with prions and apathogenic murine retrovirus particles (molecular clone Mov3 of Moloney murine leukemia virus) is changed (28) . Here, we assess the impact of a peripheral virus infection on the host immune system specifically in the brain and prion pathogenesis after intracerebral prion infection. Interestingly, prions were efficiently cleared from the brain at early time points in mice that were infected with retrovirus. Using microglia specific antibodies (9, 10), we show that clearance correlated with activation of brain microglia but not with recruitment of monocytes. Gene expression profiling revealed an activation of the lysosomal-autophagy system in microglia of retrovirus infected mice. However, early activation of microglia did not change progression to clinical prion disease. This might be caused by the fact that microglia homeostatic protein expression is lost in clinical prion disease.
MATERIALS AND METHODS

Ethics statement
Animal experiments were in strict accordance with the principles of laboratory animal care (NIH publication No. 86-23, revised 1985) and the recommendations in the Guide for the Care and Use of Laboratory Animals of the German Animal Welfare Act on protection of animals. The protocol was approved by the Ethical Committee of the Freie und Hansestadt Hamburg, Amt f€ ur Gesundheit und Verbraucherschutz (Permit numbers: G 21307/591-00. 33 and V 1300/591-00.33). All inoculations were performed under Ketamine hydrochloride and xylazine hydrochloride anesthesia, and all efforts were made to minimize suffering.
Chemicals
If not otherwise indicated, all chemicals were purchased from Sigma-Aldrich (St. Louis).
Virus production
We used the molecular clone Mov3 of replication competent Moloney murine leukaemia virus (MoMuLV), generated by transduction of mouse fibroblast NIH-3T3-cells as described (28) . NIH-3T3 mouse fibroblasts were maintained in Dulbeccos modified Eagle Medium (DMEM high glucose, PAA, Coelbe, Germany) supplemented with 10% fetal bovine serum (PAA). Cell culture supernatant of transduced cells was harvested from confluent plates, cleared by centrifugation, aliquoted and stored at 2808C for further usage. All experiments involving mouse retrovirus infection in this study were performed with the same batch of virus with an approximate titer of 10 6 infectious units (IU)/mL, as determined by XC plaque assay. Cell culture supernatant of uninfected virus free cells served as control for mock infection. Figure 1A ). Three animals of each experimental cohort were analyzed 30, 60 and 90 days after prion infection (corresponding to day 51, 81, 111 here designated P51, P81, P111, respectively). At least five animals of each experimental cohort were allowed to progress to terminal clinical prion disease (clinically presenting with slowness, ataxia, weight loss, trembling and ungroomed fur). Control animals received mock (comparable brain homogenate from uninfected CD-1 mice) or were infected with retrovirus (7 3 10 4 IU) on postnatal day 5 only.
Western blot analysis
For Western blot analysis, samples were homogenized (FastPrep FP120, Qbiogene, Illkirch, France) at 10% (weight/volume, w/v) in buffer (150 mM NaCl, 1% NP-40, 0.5% DOC, 0.1% SDS, 50 mM Tris-HCl pH 8.0) and selected samples were digested with proteinase K (PK) (20 mg/mL) (Roche, Mannheim, Germany) for 1 h at 378C. Digestion was stopped by addition of 103 sample buffer and boiling for 10 min. Samples were analyzed by SDS-page (AnykD, Biorad, Hercules), transferred to PVDF membranes (BioRad) at 400 mA for 1 h, blocked for 1 h at room temperature in proteinfree blocking buffer (Thermo Scientific, Rockfort) and incubated overnight at 48C with anti-PrP antibody Pom1 (1:1000 in blocking buffer; provided by Adriano Aguzzi, Z€ urich) (43) . After incubation for 1 h at room temperature with an HRP-conjugated anti-mouse secondary antibody (1:5000 in blocking buffer), signal was detected with ECL femto reagent (Thermo Scientific) and visualized and quantified with a BioRad ChemiDoc imaging station and Biorad VersaDoc. Quantification of relative PrP Sc amount was performed according to Zhu et al (63) . Briefly, brain homogenate (corresponding to 20 mg total protein) was PK-digested as described above and the relative signal intensity of Pom1-positive signals was measured by the ChemiDoc quantification tool.
Sodium phosphotungstic acid (NaPTA) precipitation NaPTA precipitation of brain and spleen was done according to published protocols (18) . Briefly, 100 mg tissue was dissociated in 900 mL buffer [25 mM HEPES (pH 7.2), 0.3 M sucrose and 53.6 mg Liberase Blendzyme 2 (Roche)], incubated for 30 min at 378C and homogenized (FastPrep FP120). Five hundred microliter of 10% (w/v) tissue homogenates and 500 lL of 4% (w/v) sarkosyl-PBS were vortexed, and incubated for 10 min at 378C with constant agitation. Benzonase (Novagen, San Diego) and MgCl 2 were added to 50 U/mL and 1 mM, respectively, and incubated at 378C for 30 min with vigorous agitation. To this, 81.3 lL of a pre-warmed (to 378C) 4% (w/v) NaPTA/170 mM MgCl 2 solution (pH 7.4) was added, vortexed, and incubated with vigorous agitation for 30 min at 378C. Samples were centrifuged at 25 000g for 30 min and pellets were resuspended in 22.5 lL of 0.1% sarkosyl-PBS, followed by proteinase K digestion (Roche) with a final concentration of 20 mg/mL for 45 min at 378C. Digestion was stopped by adding 103 sample buffer and boiling for 10 min. Afterward samples were processed as above.
Microglia antibodies
Different antibodies were used in this study to characterize microglia (Table 1) . While the antibody Iba1 recognizes both, microglia and recruited monocytes, the antibodies P2ry12 and 4D4 are specific for brain resident microglia. Iba1 was raised against the C-terminus of Iba1 in rabbits (#019-19741; Wako Chemicals, Neuss, Germany). Likewise, P2ry12 was raised using C-terminal peptide of mouse P2ry12 in rabbits, too, validated in (8, 9, 55) . In contrast, 4D4 was raised against a preparation of CD11b 1 /CD45 1 cells purified and sorted from mouse brain by immunizing rat, validated in Refs. 7, 10.
Immunohistochemistry
Tissues were fixed with 4% buffered formalin, inactivated by immersion in 98% formic acid for one hour, post fixed in 4% buffered formalin overnight and processed for paraffin embedding. Sections (3 mm) were subjected to HE staining and B220 (14-0452-8; eBiosciences), CD3 (A0452; Dako), p30 gag protein (ATCC number: CRL-1912 TM ), rabbit anti-P2ry12 (9) and ionized calcium binding adaptor molecule 1 (Iba1, Wako Chemicals, Neuss, Germany) immunohistochemistry using a Ventana Benchmark XT (Ventana, Tuscon, Arizona). Sections were incubated with primary antibody for 1 h, anti-rabbit or anti-mouse Histofine Simple Stain MAX PO Universal immunoperoxidase polymer (Nichirei Biosciences, Wedel, Germany) were used as secondary antibodies. Detection of secondary antibodies and counter staining was performed with an ultraview universal DAB detection kit from Ventana (Ventana, Tuscon, Arizona).
Quantification of microglia cell number was performed on Iba1 stained sections in an area of 273 000mm 2 per brain. Iba1 stained cells were counted as positive when the cell body including the nucleus was visible. For each cohort, four mice were analyzed and all analyses were performed blinded to treatment. Paradigm of the inoculation procedure with time points depicted for retrovirus/mock infection (postnatal day 5; P5) as well as prion/NBH (normal brain homogenate from CD1-mice) injections (P21). The upper scale shows age of the mice in days, whereas the lower scale shows time points of and after prion infection (dpi; days post infection). The preclinical experimental time points post prion infection and the corresponding age of the mice are depicted, respectively. B. Using standard and NaPTA enhanced Western blots developed with antibody Pom1 we could not detect differences in PrP Sc amounts at preclinical time points between brains of prion only and prion 1 virus infected mice. Asterisks (*) indicate samples that were also investigated in the tga20-bioassays. For PrP Sc -detection, mounted tissue sections (3 mm) were pretreated with 98% formic acid for 5 min. Further processing was performed on an automated staining machine (BenchMarkTX). Briefly, sections were pretreated with 1.1 mM sodium citrate-buffer (2.1 mM Tris-HCl, 1.3 mM EDTA, pH 7.8) at 958C for 30 min, digested with low concentration of protease for 16 min, incubated in Superblock for 10 min and then incubated with the PrP specific antibody Saf 84 (1:100; Cayman Chemical, Ann Arbor), followed by a biotinylated anti-mouse IgG secondary antibody.
Immunofluorescence analysis
For the detection of retroviral protein in cells, mounted sections (2 mm) from paraffin embedded tissues were dewaxed and antigen retrieval was performed for 30 min at 968C in 10 mM citrate buffer pH 6.0. Subsequently, sections were permeabilized with 0.2% TritonX-100 (Roche) in TBS. Detection of viral proteins was performed using anti-murine leukemia virus p30 gag protein (1:5 in blocking buffer; ATCC Number: CRL-1912 TM ), followed by detection with an Alexa555 labeled secondary antibody. To determine viral target cells in the brain, doublecortin (1:100 in blocking buffer; ab18723 Abcam) was detected with an Alexa488 labeled secondary antibody. For double staining's of microglia/monocytes and lysosomes, brain sections were then incubated with antibodies Iba1 and anti-Lamp1 (anti-mouse Lamp1 monoclonal antibody 1D4B developed by J. Thomas August was obtained from the Developmental Studies Hybridoma Bank developed under the auspices of the NICHD and maintained by The University of Iowa, Department of Biology, Iowa City, IA 52242) using Alexa555 and Alexa488 labeled secondary antibodies, respectively. Data acquisition was performed using a Leica Sp5 confocal microscope and Leica application suite software (LAS-AF). Iba1 stained microglia cells were chosen for Lamp1 quantification when the cell body including the nucleus was visible. For each group, three mice were analyzed and all analyses were performed blinded to treatment. Quantification of Lamp1 positive staining within microglia was performed in a according to the method described by Chapnick and Liu (11) . Briefly, microglia cells were carefully selected by free hand tool of Leica application suite software and the sum of the values of the pixels (here: Lamp1-Alexa488 positive pixels) in the selection were calculated. Fluorescence signal from 60 microglia cells was measured per group.
For double staining of resident brain microglia cells, we applied a two-step protocol. Briefly, paraffin sections were thoroughly dewaxed with antigen retrieval as above. Microgliaspecific monoclonal antibody 4D4 (7, 10) was applied overnight and, after washing, followed by incubation with Alexa488-fluorescently labeled secondary antibody. Subsequently, tissues were permeabilized with 0.2% Triton in TBS, washed and incubated overnight with an anti-Iba1 antibody. Sections were washed again; Iba1 was detected with Alexa555-labeled secondary antibody and after washing, slides were mounted with DAPI-Fluoromount-G (SouthernBiotech, Birmingham). Data acquisition was performed using a Leica Sp5 confocal microscope and Leica application suite software (LAS-AF-lite).
Determination of prion titers by mouse bioassay
Equal amounts of 1% brain homogenates were inoculated intracerebrally into groups of 4 PrP C overexpressing tga20 transgenic mice (17) . Animals were observed daily and sacrificed when severe clinical signs of prion disease (reduced motor activity, weight loss, hunched posture, hind limb paresis and ataxia) were evident. Prion titers were calculated according to the following equation valid for RML 5.0 prions (y 5 11.45 2 0.088x), where x is the incubation time to terminal disease in days and y is LD50.
Isolation and sorting of adult resident microglia cells from brain tissue
Microglia cells from 3 weeks old mice were isolated from brains of transcardially perfused mice [using ice cold Hanks buffered saline (HBSS)]. Single cells suspensions were prepared; cells were mixed with 70% Percoll (GE Healthcare, Little Chalfont) and centrifuged in a 37%/70% discontinuous gradient. Cells from the interface were collected and incubated on ice for 30 min each in subsequent steps with 4D4, Goat anti-rat APC (Biolegend, San Diego) and anti-CD11b-PE-Cy7 (BD Biosciences, Heidelberg, Germany) with washing steps in between. Fluorescence-activated cell sorting (FACS) was performed to specifically isolate CD11b1/4D41 resident brain microglia cells as described (10) (see Supporting Information Figure S4B for sorting schema). Cells were lysed in mirVana lysis buffer (Life Technologies, Darmstadt, Germany) and stored at 2808C for further analyses.
Quantitative NanoString nCounter miRNA/gene expression analysis Total RNA was isolated using the mirVanaTM miRNA isolation kit (Life Technologies, Darmstadt, Germany) according to the manufacturer's instructions. To assess differences in microglial gene expression after virus infection we used the MG468 chip that was designed for the quantitative NanoString nCounter platform. This chip detects expression profiles of genes which are specific for or highly expressed in adult mouse microglia cells, but also contains inflammation-related genes which are significantly affected in neurodegenerative/neuroinflammatory mouse models such as EAE (experimental autoimmune encephalitis), see ref. (8) for chip design. RNA (100 ng) from microglia cells of four mice of each experimental group were pooled for analysis and technical duplicates were run to increase accuracy.
Statistical analysis
For statistical comparison, Student's t-test was used with levels for statistical significance set at P-values <0.05 (*) and <0.01 (**) and <0.005 (***). Exact P values are listed in the respective figure legends.
RESULTS
Retrovirus particles have been suggested as an efficient trafficking device for prion proteins (31) . To study if the intraperitoneal infection of mice with both, retrovirus and prions lead to enhanced neuroinvasion, we chose the mouse leukemia retrovirus MoMuLV (here: molecular clone Mov3) since this virus has been shown to efficiently spread prion infectivity in vitro (31) . We established an inoculation scheme for MoMuLV that did not lead to development of MoMuLV induced leukemia during the investigated time course of a prion disease (28) . Interestingly, intraperitoneal infection with both pathogens did not lead to accelerated neuroinvasion and disease course, but to a change in the brain lesion profile and clinical prion disease presentation (28). Since it had been shown that systemic infections influence the outcome of neurodegenerative diseases, in this study we wanted to specifically address what is happening in the brain of mice during the disease course after intraperitoneal MoMuLV infection and if prion spreading within the brain is influenced by viral infection.
Our inoculation scheme (see Figure 1A ) with intraperitoneal injection of MoMuLV on postnatal day 5 established an infection without histological signs of virus pathology in the brain. No signs of virus-induced neurodegeneration, which may be observed following neonatal infection with aggressive or neurotropic virus isolates (32), were detected (Supporting Information Figure 1 ). MoMuLV or Mock infected mice were intracerebrally infected with prions at day 21 using low or high titers of RML prions ( Figure 1A ). As brain injection control, we used brain homogenate from uninfected mice [normal brain homogenate (NBH)]. Following intracerebral injection, prions are rapidly cleared from the CNS and reappear in lymphoreticular organs particularly the spleen (57) . In NaPTA enhanced Western blots, PrP Sc was detectable in spleen 30, 60 and 90 days post infection (dpi) (data not shown). In brain, PrP Sc could not be detected at 30 dpi (for both cohorts) and 60 dpi (for low dose prions) but was abundant at 60 dpi (for high dose prions) and 90 dpi (for both cohorts) with increasing prion loads over time, yet independent of MoMuLVinfection ( Figure 1B ).
Infectious prions are efficiently cleared from the brain at early time points in retrovirus infected animals
Since prion infectivity is not directly congruent with PrP Sc , we were interested to see if MoMuLV-infection influenced prion titers in brain and spleen at preclinical time points. Thus, we determined prion titers in these organs by tga20-bioassay from mice 30 and 60 dpi (Figure 2A-D) . Prion titers in spleen were comparable in all tested instances and ranged between 3.5 and 5 logLD50/mL tissue with no significant increase over time or modulation by MoMuLV (Figure 2A) . Unexpectedly, infection with MoMuLV dramatically affected prion titers in brain: here, in contrast to controls, prion In cerebellum, we could detect comparable effects in the bioassay at 60 dpi after low dose infection. ***P < 0.0001.
infectivity was undetectable at 30 dpi (high dose prions; Figure 2B ) and 60 dpi (low dose prions; Figure 2C ). To rule out brain region dependent differences and influence of residual prion infectivity from the inoculum, we performed bioassay of cerebellum, a brain region distant from the inoculation site at 60 dpi. As above, prion infectivity was absent in mice inoculated with prions and MoMuLV whereas control cerebellum samples contained high prion titers in low dose inoculated animals ( Figure 2D ). Interestingly, in the cohort of mice receiving high dose prions, brain as well as cerebellum titers of infectious prions developed to control levels 60 dpi in the MoMuLV cohort pointing to a transient prionostatic effect (Figure 2B and D) .
MoMuLV activate microglia but does not lead to recruitment of peripheral monocytes to the brain
PrP
C is a host encoded protein, thus there is almost no measurable immune response after prion inoculation (44) . To investigate why prion titers were undetectable in brains of retrovirus infected mice, we stained immune cells and astrocytes in the brain of retrovirus and mock infected mice on P21. Of note, this is the time point where these mice would be infected with prions. Figure 3A) . However, the number of Iba1 1 microglia cells was significantly higher in all investigated brain regions in MoMuLV-infected mice when compared with age matched mock control mice ( Figure 3B and C) . Microglia cell numbers in MoMuLV-infected mice returned to normal levels within 30 days and remained stable ( Figure 3C ). The microglial activation in prion-challenged mice at later time points was unaffected by additional MoMuLV infection (Supporting Information Figure 2) .
The number of B-and T-cells or astrocytes did not change upon MoMuLV-infection with generally very low numbers of B-and Tcells in brain parenchyma (
Next, we wanted to address why microglia number is increased in virus infected mice. Since it is unknown if intraperitoneally applied MoMuLV, a leukemia virus, could traffic to the brain and infect brain resident cells we performed immunohistochemical staining against the viral p30 protein (Supporting Information Figure S3A-F) . Interestingly, we could detect MoMuLV only in the lateral ventricle (Supporting Information Figure S3B ), the dentate gyrus of the hippocampus (Supporting Information Figure S3C ), and the rostral migratory stream (Supporting Information Figure  S3D ) (see squared regions in Supporting Information Figure S3A ). Since these regions are known to be involved in adult neurogenesis (35), we performed immunofluorescence staining against p30 and doublecortin and could show that MoMuLV resides in doublecortin positive cells (Supporting Information Figure S3E ). Of note, we could not detect direct infection of microglia by MoMuLV. To elucidate temporal kinetics of MoMuLV entry in the mouse brain, we performed immunoflourescence stainings against p30 at several time points. Only in virus-infected mice but not in mock-infected control mice were we able to detect viral protein p30 in brain as early as 16 days post infection (Supporting Information Figure  S3F ). Interestingly, amount or distribution of detectable viral protein abundance did not change over time.
Microglia may represent a heterogeneous population of immune cells made up of bona fide brain derived microglia and recruited peripheral monocytes. To determine to which extent both cell types contribute to microgliosis seen upon MoMuLV-infection at early time points, we used antibodies specific to resident microglia cells (7, 9, 10, 21, 55) . Staining with Iba1 and a microglia specific P2ry12 antibody showed upregulation of microglia number in virus infected brains compared with mock control ( Figure 3D ). All cells show double staining with Iba1 more pronounced in the cell body of microglia, while P2ry12, as membrane protein, staining the processes. No Iba1
-monocytic cell could be detected in the brain parenchyma of both investigated groups ( Figure 3D ). These data were confirmed by double fluorescence staining with Iba1 and microglial specific 4D4 (Supporting Information Figure S4A ). Both again showed increase in microglia number in MoMuLVinfected mice compared with mock controls, but no recruitment of monocytes (Supporting Information Figure S4A and S4B).
Lysosomal activation in microglia associated with prion clearance
Next, we wanted to determine whether microglia triggered by retrovirus display a distinct expression profile that enable prion clearance. To investigate the molecular signature of microglia after virus contact at the time of prion clearance, we isolated RNA from of 4D4
1
/CD11b
1 FACS sorted resident brain microglia cells of 21-day-old mice after virus or mock infection (see Supporting Information Figure S4C ). After evaluating the RNA quality by qPCR (data not shown), we performed gene expression analysis using the custom Ncounter microglia MG468 chip (8) . This chip directly quantifies mRNA transcript numbers of genes that are specific for or highly expressed in adult mouse microglia cells including marker genes for the hypothetical microglia activation groups M1-(Caspase1, IL1b, NOS2) and M2 (FIZZ1, Arg1, IL4, IL10).
Only a small subset of the tested microglial genes was downregulated upon MoMuLV-infection compared with microglia from mock control mice. These included: transcription factors (Fosb, Atf3), a chemokine (Ccl4) and genes implicated in cell migration (Vegf, Nav2) ( Figure 4A) . Surprisingly, MoMuLV-infection did not affect expression of typical M1 or M2 inflammatory signaling ( Figure 4B ). As expected, genes known to be involved in the antiviral response of the immune system were upregulated (complement C1qb, and Toll like receptor-1, Tlr1). Further significantly upregulated genes are linked to metabolism of nucleotides (Pde3b, Entpd1), transcription (Mef2a, Mafb), G-protein coupled receptors (Adrb1, Gpr56), Kinases and GTPase (Cables1, Tagap) in addition to proteins with yet unknown function in microglia homeostasis (Crybb1, Tmem119, Tmem86a). The greatest number of upregulated genes belonged to protein degradation machinery (Serpine2, Snx24, Ctsd, Ctsl, Ctss, Usp2). Involvement of lysosomal protein degradation is active in prion disease and stimulation of this pathway leads to prion clearance (27, 36) . This led us to investigate if lysosomal degradation in microglia cells is changed. Therefore, we stained brain sections with Iba1 and the lysosomal marker protein Lamp1 ( Figure 4C ). Lamp1-positive lysosomes were increased 30 days after MoMuLV-infection when compared with mock control mice ( Figure 4C ), a time point correlating with increased clearance or delay in generation of infections prions from brains of MoMuLV-infected mice. Quantification of Lamp1/Alexa488 positive staining/microglia cell confirmed significant increase of lysosome amount in microglia of virus infected mice ( Figure 4D ).
Microglia homeostasis is severely disturbed in clinical prion disease
Although we could detect reduction of infectious prion titers at early time points, incubation time to clinical prion disease ( Figure  5A ), PrP Sc -amounts in brain tissue and the PrP Sc glycopattern were unchanged upon MoMuLV-infection ( Figure 5B, C) . The PrP Sc deposition pattern of misfolded prion protein in different brain regions was assessed by immunohistochemistry. Again, we could not detect differences between animals infected with prions vs. those infected with prions 1 virus ( Figure 5D ). As previously reported, the clinical presentation of the prion disease of mice after intraperitoneal prion injection changes upon an additional retrovirus infection (28) . However, changes were less pronounced in the intracerebrally infected when compared with intraperitoneally prion infected mice (data not shown).
To evaluate expression of homeostatic marker protein P2ry12 in microglia of clinically prion-diseased mice, we stained consecutive brain sections for Iba1 and P2ry12, respectively. The latter protein is highly specific for brain resident homeostatic microglia (8, 9, 55) . Moreover, P2ry12 has been implicated as a critical receptor for process motility and seems to be involved in alerting resting microglia to direct them to the side of injury in the brain (21, 55) . Interestingly, P2ry12 reactivity is completely lost in the thalamus and cerebellum of clinically prion diseased mice, whereas Iba1 staining show typical pattern of highly activated microglia ( Figure 6A ). In contrast, there is still expression detectable in the hippocampus. Of note, P2ry12 downregulation correlate with PrP Sc deposition pattern in RML-prion infected mice. In age matched healthy control, both antibodies stain comparable numbers of cells ( Figure 6A, B) . Quantification of P2ry12-positive cells confirms significant loss of P2ry12 in clinical prion disease ( Figure 6B ). This may explain why microglia progressively failed to respond to PrP Sc during prion disease.
DISCUSSION
The role of microglia in neurodegeneration is not fully understood and although these cells are able to clear misfolded proteins, they acquire detrimental effects in the course of a neurodegenerative disease (19, 23) . Here we show that retrovirus-induced activation of microglia correlate with transient clearance of prions from the brain in early murine prion disease. This effect was restricted to the brain as prion infectivity was unchanged in lymphoreticular system.
Microglia has been recently shown to play an important and protective role in prion pathogenesis, since pharmacogenetic microglia depletion enhanced neurotoxicity and accelerated prion disease course (62) . However, the PrP Sc -clearing potential of microglia is limited (24) . LPS-induced microglial stimulation does not lead to enhanced prion clearance (24) . Manipulation of microglial proteins, for example, inhibition of Colony stimulating factor 1 receptor (CSF1R) reducing microglia proliferation and activity, slowed neuronal damage and disease progression (19) . Knockout of CD14 leading to the expression of anti-inflammatory cytokines of the M2-type also delayed disease progression (51) . Interestingly, knockout of Trem2, a microglial receptor implicated in the pathogenesis of AD, did not influence prion disease pathophysiology (63) .
The roles of recruited monocytes and brain-endogenous microglia are distinct regarding their contribution to neurodegenerative diseases (9, 34, 46) . The impact of recruited monocytes in murine prion models is unclear and technical restrictions have hampered interpretation (45, 46) . Recent data rather point to a minor role of monocytes for the progression of murine prion diseases (19) . Using microglia specific antibodies (9, 10), we could show that in MoMuLV infected animals the number of microglia is increased in the absence of recruitment of monocytes to the brain suggesting selective activation of parenchymal microglia.
It is still a matter of debate whether activation of the immune system by systemic infection is beneficial or detrimental in chronic neurodegenerative diseases (13, 22, 39) . Several studies have addressed the neuropathological changes associated with neurovirulent mouse retroviruses (32, 58) . These virus species efficiently infect microglia and/or endothelial cells after intracerebral infection (61) , rapidly induce sickness behavior and severe neuropathological changes including microglia activation, neuronal loss and/or spongiform changes and overt disease (56) . We deliberately choose an inoculation scheme that does not lead to sickness behavior or neuropathological changes. Nonetheless, MoMuLV colonize the CNS following peripheral injection. Highest presence of viral proteins was observed in doublecortin positive cells in areas compatible with neuronal stem cell niches (35) . Recently, it has been shown that neuronal stem cells efficiently accumulate and replicate prions (49) . Therefore, double infection of neuronal stem cells with both pathogens might lead to increased prion spreading in the brain from these cells in virus infected mice, thereby potentially counteracting the beneficial effect of microglia activation seen in these mice at preclinical disease stages. Moreover, infection of the stem cell niche with both pathogens might be responsible for the changes in the lesion profile in mice infected with both pathogens as compared with mice with prion infection only (28) .
In our model, infection with MoMuLV correlated with transient clearance or a delay in accumulation of infectious prions but did not affect disease kinetics. It is therefore possible that prion replication in lymphoreticular organs such as spleen, not subject to prion clearance, led to rapid prion-colonization of the brain once the homeostatic function of microglia is compromised. Our finding of complete loss of the homeostatic P2ry12 protein expression at clinical prion disease might support rapid and substantial changes in microglia phenotype early in prion disease, as has been shown for the SOD1-mouse model of ALS and human ALS (8) . Alternatively, it is possible that non-infectious subset of prion species might represent a reservoir in these mice leading to reoccurrence of infectious prions and prion disease. A recent article of Sandberg et al (52) implies existence of distinct types of PrP Sc in the brain differing mainly in their neurotoxic potential. Analyses of hamster prions showed that different prion aggregation states vary in their infectious potential suggesting small oligomers as the most infectious unit (54) . This leads to the question which prion subtype might have been degraded by activated microglia in our approach? Considering the article of Silveira, oligomeric protein species could be an obvious target (54) .
Since we did not observe any overt neuronal loss in MoMuLV infected animals as would be expected for a cytotoxic action, virusactivated microglia might rather act on extracellular PrP. Microglia primed to target viral particles might efficiently eliminate other small vesicles such as exosomes, which have been implicated in the pathophysiology of prion diseases (16, 20, 31, 50) and other neurodegenerative diseases (4, 14) . The similarities in the composition of retrovirus particles and exosomes have been stressed by several studies (3, 25) . Here, it would be interesting to see whether repeated stimulation with viral proteins is possible and might lead to prolonged prionostatic effects. However, to avoid putative negative side effects of active viral replication in neuronal stem cells, the spiking of exosomes with viral proteins might be a feasible alternative to trigger microglia activation. Microglia function changes with age and with disease progression (9, 37) . In our experimental setup, microglia coming from very young animals were profiled. Upregulation of gene expression as determined by Ncounter nanostring-analysis in our model was surprisingly mild and dominated by an induction of genes associated with protein degradation. We performed expression profiling of a set of genes, relevant for microglia homeostasis and function, 16 days after virus infection, representing a snapshot of MoMuLVactivated microglia at the time point of prion challenge. It is likely that observed effects may not be achieved at later time points in the disease course, since microglia lose their homeostatic functions quite rapidly.
We saw that surprisingly mild changes in microglia signature correlated with clearance of infectious prion from the brain. Given the total loss of homeostatic P2ry12 protein expression at clinical prion disease, therapeutic strategies aimed at restoring homeostatic microglial signaling and function may be more promising than therapies aimed at activating microglia.
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SUPPORTING INFORMATION
Additional Supporting Information may be found in the online version of this article at the publisher's web-site: Figure S1 . Intraperitoneal infection with the molecular clone Mov3 of Moloney murine leukaemia virus (MoMuLV) does not lead to pathological changes in the brain. Neuropathogenic murine leukaemia virus strains lead to rapid spongiform vacuolar neurodegeneration with a syndrome characterized by tremor, ataxia, hind limp weakness and paralysis. In contrast, the here investigated molecular clone Mov3 of MoMuLV does not lead to any detectable change in brain tissue when compared with brains of mock control mice. Moreover, mice behaved normally and did not show any sign of progressive neurodegeneration. Three representative brain regions of MoMuLV infected mice are compared here with those of mock control mice at P21 (comparable to the day of prion infection) (n 5 3/group) (scale bars 50 mm each). Figure S2 . MoMuLV-infection does not affect Iba1-positive microglia in advanced prion disease. Representative brain regions were analyzed for Iba1-positive microglia at two preclinical time points (30 and 90 days post high dose infection) and at clinical prion disease or corresponding time points for all four experimental cohorts. Whereas microglia activation is unchanged in NBH control and virus only infected mice at all assessed time points, Iba1-positive microglia increased and change to an activated phenotype in the course of prion disease independent of an additional retrovirus infection (Scale bar 20 mm) (n 5 3-5/group). 
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1 microglia sorted from intra peritoneal retrovirus infected mice or mock injected controls 16 days post injection.
